文献速递消化系统肿瘤

FOLFOXIRI联合贝伐珠单抗作为初始不可切除转移性结直肠癌转化治疗的系统综述与汇总分析

FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
PubMed 文献 · JAMA Oncol · 2017-07-13

该系统综述与汇总分析纳入2010至2016年发表的11项FOLFOXIRI联合贝伐珠单抗研究、共889例初始不可切除转移性结直肠癌患者,客观缓解率为69%(95%CI 65%-72%;I2=25%),总体手术转化率为39.1%(95%CI 26.9%-52.8%),R0手术转化率为28.1%(95%CI 18.1%-40.8%),中位总生存期30.2个月(95%CI 26.5-33.7个月),中位无进展生存期12.4个月(95%CI 10.0-14.3个月)。

要点

  • FOLFOXIRI联合贝伐珠单抗治疗初始不可切除转移性结直肠癌的客观缓解率为69%(95%CI 65%-72%;I2=25%)。
  • 总体手术转化率为39.1%(95%CI 26.9%-52.8%),R0手术转化率为28.1%(95%CI 18.1%-40.8%)。
  • 中位总生存期30.2个月(95%CI 26.5-33.7个月),中位无进展生存期12.4个月(95%CI 10.0-14.3个月)。

核心结论

  • 对于手术不可切除的转移性结直肠癌患者,FOLFOXIRI联合贝伐珠单抗与显著的客观缓解率相关,该有效方案使远处转移的手术转化概率接近40%,超过四分之一患者实现R0切除。

研究设计与样本

  • 系统综述与汇总分析,遵循PRISMA指南于2016年10月检索PubMed、Cochrane Central Register of Controlled Trials、SCOPUS、Web of Science、Google Scholar、CINAHL、Ovid和EMBASE,检索词为FOLFOXIRI和bevacizumab及(colorectal cancer)。
  • 纳入使用FOLFOXIRI联合贝伐珠单抗治疗人类初始不可切除转移性结直肠癌的临床试验、回顾性病例系列和前瞻性病例系列;排除个别病例报告和少于10例患者的回顾性病例系列。
  • 最终纳入2010至2016年发表的11项研究,共889例患者,其中877例可临床评估客观缓解率;由2名评价者独立提取数据,采用随机效应模型并按各试验纳入患者数加权汇总疗效效应量。

主要发现

  • FOLFOXIRI联合贝伐珠单抗的客观缓解率为69%(95%CI 65%-72%;I2=25%)。
  • 总体手术转化率为39.1%(95%CI 26.9%-52.8%),R0手术转化率为28.1%(95%CI 18.1%-40.8%)。
  • 在有数据可用的6项试验中,汇总中位总生存期为30.2个月(95%CI 26.5-33.7个月);在有数据可用的9项试验中,中位无进展生存期为12.4个月(95%CI 10.0-14.3个月)。
  • Meta回归分析中,与转化手术显著相关的变量为疾病局限于肝脏和较高的中位周期数(接近12)。

关键数值与推荐

  • 客观缓解率69%(95%CI 65%-72%;I2=25%),基于877例可临床评估患者。
  • 总体手术转化率39.1%(95%CI 26.9%-52.8%),R0手术转化率28.1%(95%CI 18.1%-40.8%)。
  • 中位总生存期30.2个月(95%CI 26.5-33.7个月),基于6项有数据可用的试验。
  • 中位无进展生存期12.4个月(95%CI 10.0-14.3个月),基于9项有数据可用的试验。
  • 与转化手术显著相关的变量:疾病局限于肝脏和较高的中位周期数(接近12)。

临床怎么用

  • 对于手术不可切除的转移性结直肠癌患者,FOLFOXIRI联合贝伐珠单抗与显著的客观缓解率相关,该有效方案使远处转移的手术转化概率接近40%,超过四分之一患者实现R0切除。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer. However, resection rates of metastases and overall survival with this schedule have never been systematically evaluated in published studies including, but not limited to, the TRIBE (TRIplet plus BEvacizumab) trial. OBJECTIVE: To assess the clinical efficacy of FOLFOXIRI-Bev, including outcomes and rates of surgical conversions. DATA SOURCES: A systematic review was conducted in October 2016 in concordance with the PRISMA guidelines of PubMed, the Cochrane Central Register of Controlled Trials, SCOPUS, Web of Science, Google Scholar, CINAHL, Ovid, and EMBASE using the terms FOLFOXIRI and bevacizumab and (colorectal cancer). STUDY SELECTION: Clinical trials, retrospective case series, and prospective case series that used FOLFOXIRI-Bev for the treatment of initially unresectable metastatic colorectal cancer in humans were included. Individual case reports and retrospective case series with fewer than 10 patients were excluded. DATA EXTRACTION AND SYNTHESIS: Data were extracted independently by 2 reviewers on a predesigned, standardized form. Ultimately, data were aggregated to obtain the pooled effect size of efficacy, according to the random-effects model and weighted for the number of patients included in each trial. MAIN OUTCOMES AND MEASURES: Median overall survival and progression-free survival, overall response rates, and rates of R0 surgical conversions and overall surgical conversions. RESULTS: Eleven FOLFOXIRI-Bev studies published between 2010 and 2016 met the inclusion criteria and were pooled for analysis. The studies included 889 patients, with 877 patients clinically evaluable for overall response rates. The objective response rate to FOLFOXIRI-Bev was 69% (95% CI, 65%-72%; I2 = 25%). The rate of overall surgical conversions was 39.1% (95% CI, 26.9%-52.8%), and the rate of R0 surgical conversions was 28.1% (95% CI, 18.1%-40.8%). Median pooled overall survival was 30.2 months (95% CI, 26.5-33.7 months) in 6 trials with data available, and progression-free survival was 12.4 months (95% CI, 10.0-14.3 months) in 9 trials with data available. In meta-regression analysis, variables significantly associated with conversion surgery were disease limited to the liver and a higher median number of cycles (close to 12). CONCLUSIONS AND RELEVANCE: For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate. Such an effective regimen leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. JAMA Oncol. 2017. PMID: 28542671. doi:10.1001/jamaoncol.2017.0278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。